A promising new HIV vaccine has successfully passed initial trials on 33 HIV-positive patients, and will now be tested on 600 people who do not suffer from the illness to find out its ability to prevent infection.
The results of the first tests of the vaccine, dubbed SAV001, have been published in the journal Retrovirology. It is a ‘killed whole-HIV-1 vaccine’, which means that it contains the virus itself, but modified and already harmless for the human body. The vaccine aims at producing anti-HIV antibodies in uninfected patients. Continue reading “Canadian scientists to test promising HIV vaccine on 600 volunteers”